HSP90


Also found in: Acronyms, Wikipedia.

HSP90

A generic term for a family of molecular chaperones which play a key role in protein folding and quality control for a range of client proteins. Functional HSP90s operate as dimers, have intrinsic ATPase activity, act in concert with other chaperones (e.g., HSP70) and are regulated by co-chaperones/accessory proteins (e.g., HOP, CDC37). HSP90s interact with more than 100 proteins, including kinases (e.g., Raf-1), nuclear hormone receptors (e.g., oestrogen receptor), transcription factors (e.g., P53), GPCRs (e.g., CB2 receptors) and ion channels (e.g. CFTR). In humans, the HSP90-beta isoform is constitutively expressed (i.e., at baseline), whereas HSP90-alpha isoforms are induced by stress. HSP90 plays an important role in some tumour cell types by stabilising mutated oncogenic proteins.
References in periodicals archive ?
Primary antibodies were used at the following concentrations in TBST: mouse HSP90 (Stressgen, Victoria, BC, Canada; SPA-830), 1:1,000; mouse HSP70 (Stressgen, Canada; SPA-820), 1:1,000; mouse HSP60 (Abeam, Cambridge, UK; LK-1), 1:2,000; and mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Earthox, San Francisco, CA, USA; E021010-01), 1:4,000.
7, Hsp70, Hsp90 and heat shock cognate protein) were reported expressed highly in B.
The transcript levels of JHi and HSP90 were significantly up-regulated at 24, 48, 72, and 120 h and at 24, 48, 72, and 96 h, respectively, after virus infection (Fig.
incognita Hsp90 were obtained RACE (Invitrogen) was adopted in the amplification for 5' and 3' end sequences (PCR reaction primers in the studyseen in the following table).
By studying the HSP90 of the pathogen from every possible angle, Wang found another pocket capable of binding inhibitory substances, completely absent in its human alter ego.
Debio 0932, an oral HSP90 inhibitor is being developed by Curis' collaborator, Debiopharm, for multiple oncology indications.
The chaperones HSP70, HSP90 (in eukaryotes), and HSP40 have the potential to inhibit Hsfl and [sigma] 32.
Such forward-looking statements include those regarding the Company's expectations about: the timing of data and updates from clinical trials of its PI3K and Hsp90 programs; its ability to execute on its strategic plans; the therapeutic potential of its PI3K inhibitors and retaspimycin HCl; its 2013 research and development goals, including without limitation clinical and nonclinical development plans, for its PI3K program and its Hsp90 program; and dose optimization strategies.
Blots were hybridized overnight at 4 [degrees]C with the appropriate antibody: eNOS mouse monoclonal antibody (1:200 dilution; Santa Cruz Biotechnology); caveolin-1 rabbit polyclonal antibody (1:200 dilution; Santa Cruz Biotechnology), Hsp90 rabbit polyclonal antibody (1:200 dilution; Santa Cruz Biotechnology), porin mouse monoclonal antibody (3 mg/L; Abcam), or CRP rabbit polyclonal antibody (1:200 dilution; Sigma-Aldrich).
Completing a Phase 1 clinical study of IPI-940, the company's novel inhibitor of fatty acid amide hydrolase; * Reporting results from the Phase 2 clinical study of IPI-504, a novel Hsp90 chaperone inhibitor, in patients with non-small cell lung cancer and initiating further clinical development of IPI-504 in this disease;